Abstract　No 1876
|
Phase II study of weekly paclitaxel and weekly carboplatinum in recurrent platinum sensitive ovarian cancer
Category: Gynecologic Cancer Author:
C. J. Dunton; Albert Einstein Healthcare Ntwrk, Philadelphia, PA Methods: Under IRB approval, 20 patients with recurrent platinum sensitive ovarian cancer were treated with a regimen of weekly Paclitaxel (80 mg/m2) and weekly Carboplatinum (AUC 2). Patients were evaluated for response by both clinical and radiographic methods and CA-125 response by the Restin criteria. Toxicities were graded according to the common toxicity criteria. Patients were treated from 1999 through 2002. The mean platinum-free interval was 20.9 months with a range of 8-56 months. Seventeen patients were evaluable by clinical methodology and 18 patients by CA-125 response. Patients were eligible if more than 6 months since treatment with platinum containing compounds and clinical evidence of recurrence or a CA-125 which was doubling and greater than 70. Patients were evaluated for response after 8 cycles of treatment. Results: The 20 patients received an average of 13.4 cycles of treatment (range 2-18). Of the 17 patients with clinically evaluable disease, 9 had a complete response, 5 had a partial response and 3 had stable disease. In the 18 patients evaluable by the Restin criteria showed 14 patients with a complete response and 4 patients had a partial response stable disease. Overall response rate by clinical criteria was 82%(14/17) and by CA125 100%(18/18). Toxicities included Grade 3 neutropenia in 20% (4/20), Grade 2 neurotoxicity in 10% (2/20), allergic reactions in 15% (3/20) and Grade 3 anemia in 5% (1/20). The median progression free survival was 11.2 months with a range of 2-24 months. Conclusions: Weekly paclitaxel and weekly carboplatinum are a highly effective and well-tolerated regimen. Allergic reactions are no more common than in standard retreatment regimens. This dose scheduling deserves consideration for front line therapy. |